Progression of multiple system atrophy (MSA): A prospective natural history study by the European MSA study group (EMSA SG)

Movement Disorders

Volumn 21, Issue 2, 2006, Pages 179-186

  Geser, Felix ^a   Wenning, Gregor K ^a   Seppi, Klaus ^a   Stampfer Kountchev, Michaela ^a   Scherfler, Christoph ^a   Sawires, Martin ^a   Frick, Carolin ^a   Ndayisaba, Jean Pierre ^a   Ulmer, Hanno ^a   Pellecchia, Maria T ^b   Barone, Paolo ^b   Kim, Hee T ^c   Hooker, Juzar ^c   Quinn, Niall P ^c   Cardozo, Adriana ^d   Tolosa, Eduardo ^d   Abele, Michael ^e   Klockgether, Thomas ^e   Østergaard, Karen ^f   Dupont, Erik ^f   Schimke, Nicole ^g   Eggert, Karla M ^g   Oertel, Wolfgang ^g   Djaldetti, Ruth ^h   Poewe, Werner ^a   Dodel, Richard ^e   Tison, François ⁱ   Ghorayeb, Imad ⁱ   Pollak, Pierre ⁱ   Kölensperger, Martin ⁱ   Diem, Anja ⁱ   Deuschl, Günther ⁱ   Daniels, Christine ⁱ   Kopper, Florian ⁱ   Sampaio, Cristina ⁱ   Coelho, Miguel ⁱ   Ferreira, Joaquim ⁱ   Rosa, Mário M ⁱ   Pirtosek, Zvezdan ⁱ   Lees, Andrew J ⁱ   Brooks, David J ⁱ   Fowler, Clare ⁱ   Revesz, Tamas ⁱ   Gerhard, Alexander ⁱ   Holton, Janice ⁱ   Schrag, Anette ⁱ   Wood, Nick ⁱ   Bozi, Maria ⁱ   Scaravilli, Tomaso ⁱ   Lindvall, Olle ⁱ   Widner, Håkan ⁱ   Nilsson, Christer F ⁱ   Grabowski, Martin ⁱ   Krisp, Andrea ⁱ   Möller, Corsten ⁱ   Albanese, Alberto ⁱ   del Sorbo, Francesca ⁱ   Carella, Francesco ⁱ   Meco, Giuseppe ⁱ   Colosimo, Carlo ⁱ   Berciano, Jose ⁱ   Gonzalez Mandly, Andres ⁱ   Giladi, Nir ⁱ   Gurevich, Tanya ⁱ   Rascol, Olivier ⁱ   Galitzky, Monique ⁱ   Ory, Fabienne ⁱ   Gasser, Thomas ⁱ   Kamm, Christoph ⁱ   Buerk, K ⁱ   Maass, Sylvia ⁱ   Aquilonius, Sten Magnus ⁱ   Bergquist, Jonas ⁱ   more..

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF BARCELONA   (Spain)

^e UNIVERSITY OF BONN   (Germany)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g PHILIPPS UNIVERSITY MARBURG   (Germany)

^h RABIN MEDICAL CENTER   (Israel)

ⁱ NONE

Author keywords

Multiple system atrophy; Progression; Sensitivity to change; Unified MSA Rating Scale

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DAILY LIFE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; EUROPE; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; METHODOLOGY; MOTOR PERFORMANCE; NEUROPROTECTION; PREDICTION; PRIORITY JOURNAL; RATING SCALE; SENSITIVITY ANALYSIS; SHY DRAGER SYNDROME; TREATMENT PLANNING; VALIDATION PROCESS;

ADULT; AGED; CEREBELLAR ATAXIA; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; NEUROLOGIC EXAMINATION; PARKINSONIAN DISORDERS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 33644947758     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20678     Document Type: Article

References (29)

1. Weaning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol 2004;3:93-103.
2. Geser F, Stampfer-Kountchev M, Seppi K, et al. The clinical presentation of multiple system atrophy (MSA) in Europe: an interim analysis of the EMSA-SG (European MSA-Study Group) Registry. Mov Disord 2004;19(Suppl. 9):347.
3. Weaning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994;117(Pt 4):835-845.
4. Saito Y, Matsuoka Y, Takahashi A, Ohno Y. Survival of patients with multiple system atrophy. Intern Med 1994;33:321-325.
5. Schulz J, Klockgether T, Petersen D, et al. Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT. J Neurol Neurosurg Psychiatry 1994;57:1047-1056.
6. Testa D, Filippini G, Farinotti M, Palazzini E, Caraceni T. Survival in multiple system atrophy: a study of prognostic factors in 59 cases. J Neurol 1996;243:401-404.
7. Müller J, Wenning GK, Jellinger K, et al. Progression of Hoehn and Yahr stages in parkinsonian disorders: a clinicopathologic study. Neurology 2000;55:888-891.
8. Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 2002;125:1070-1083.
9. Klockgether T, Ludtke R, Kramer B, et al. The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain 1998;121(Pt 4):589-600.
10. Seppi K, Yekhlef F, Diem A, et al. Progression of parkinsonism in multiple system atrophy. J Neurol 2005;252:91-96.
11. Weaning G, Tison F, Ben-Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 1997;12:133-147.
12. Weaning GK, Tison F, Seppi K, et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord 2004;19:1391-1402.
13. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Auton Nerv Syst 1998;74: 189-192.
14. Wenning G, Ben-Shlomo Y, Magalhäes M, Quinn NP. Clinicopathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatry 1995;58:160-166.
15. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol 2001;58:1611-1615.
16. Lee C, Schulzer M, Mak EK, et al. Clinical observations on the rate of progression of idiopathic parkinsonism. Brain 1994;117:501-507.
17. Louis E, Tang MX, Cote L, et al. Progression of parkinsonian signs in Parkinson disease. Arch Neurol 1999;56:334-337.
18. Poewe WH, Weaning GK. The natural history of Parkinson's disease. Ann Neurol 1998;44(Suppl. 1):S1-S9.
19. Goetz C, Stebbins GT, Blasucci LM. Differential progression of motor impairment in levodopa-treated Parkinson's disease. Mov Disord 2000;15:479-484.
20. Olanow C, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38:771-777.
21. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59:1937-1943.
22. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-1053.
23. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
24. Colosimo C, Merello M, Pontieri F. Amantadine in parkinsonian patients unresponsive to levodopa: a pilot study. J Neurol 1996; 243:422-425.
25. Fetoni V, Soliveri P, Monza D, Testa D, Girotti F. Affective symptoms in multiple system atrophy and Parkinson's disease: response to levodopa therapy. J Neurol Neurosurg Psychiatry 1999;66:541-544.
26. Rossi P, Colosimo C, Moro E, Tonali P, Albanese A. Acute challenge with apomorphine and levodopa in Parkinsonism. Eur Neurol 2000;43:95-101.
27. Tison F, Yekhlef F, Chrysostome V, et al. Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease. Mov Disord 2002;17:701-709.
28. Quinn N, Marsden CD. The motor disorder of multiple system atrophy (editorial). J Neurol Neurosurg Psychiatry 1993;56:1239-1242.
29. Litvan I, Goetz CG, Jankovic J, et al. What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol 1997;54:937-944.